Neurogene reports Phase 1/2 gene therapy data for Rett syndrome

June 29, 2026 7:01 AM

Neurogene Inc. (Nasdaq: NGNE) announced updated data from its Phase 1/2 clinical trial of NGN-401, an investigational gene therapy for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found